NASDAQ:BWAYBRAINSWAY LTD/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BRAINSWAY LTD/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.27 +0.27 (+3.38 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$7.95Now: $8.27▼$8.2750-Day Range$7.30MA: $8.00▼$8.5552-Week Range$5.10Now: $8.27▼$12.53Volume2,870 shsAverage Volume3,932 shsMarket Capitalization$89.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBRAINSWAY LTD/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, BRAINSWAY LTD/S has a potential upside of 33.0% from its current price of $8.27.Amount of Analyst CoverageBRAINSWAY LTD/S has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesBRAINSWAY LTD/S has received 28 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBRAINSWAY LTD/S has received 31 “underperform” votes. (Add your “underperform” vote.)Community SentimentBRAINSWAY LTD/S has received 52.54% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BRAINSWAY LTD/S and other stocks. Vote “Outperform” if you believe BWAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BWAY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBRAINSWAY LTD/S does not currently pay a dividend.Dividend GrowthBRAINSWAY LTD/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BRAINSWAY LTD/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 17.26% of the stock of BRAINSWAY LTD/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BRAINSWAY LTD/S are expected to grow in the coming year, from ($0.48) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BRAINSWAY LTD/S is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BRAINSWAY LTD/S is -16.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBRAINSWAY LTD/S has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BWAY Previous Symbol CUSIPN/A CIKN/A Webwww.brainsway.com Phone972-2581-3140Debt Debt-to-Equity RatioN/A Current Ratio4.29 Quick Ratio4.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.10 million Price / Sales3.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book3.69Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-10,330,000.00 Net Margins-44.71% Return on Equity-48.90% Return on Assets-28.03%Miscellaneous Employees96 Outstanding Shares10,820,000Market Cap$89.48 million Next Earnings Date6/3/2020 (Estimated) OptionableNot Optionable NASDAQ:BWAY Rates by TradingView Receive BWAY News and Ratings via Email Sign-up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter. BRAINSWAY LTD/S (NASDAQ:BWAY) Frequently Asked Questions How has BRAINSWAY LTD/S's stock been impacted by COVID-19 (Coronavirus)? BRAINSWAY LTD/S's stock was trading at $8.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BWAY shares have increased by 1.0% and is now trading at $8.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BRAINSWAY LTD/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BRAINSWAY LTD/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BRAINSWAY LTD/S. When is BRAINSWAY LTD/S's next earnings date? BRAINSWAY LTD/S is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for BRAINSWAY LTD/S. How were BRAINSWAY LTD/S's earnings last quarter? BRAINSWAY LTD/S (NASDAQ:BWAY) posted its quarterly earnings results on Monday, March, 23rd. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.02. The firm had revenue of $6.29 million for the quarter, compared to analysts' expectations of $6.25 million. BRAINSWAY LTD/S had a negative return on equity of 48.90% and a negative net margin of 44.71%. View BRAINSWAY LTD/S's earnings history. What guidance has BRAINSWAY LTD/S issued on next quarter's earnings? BRAINSWAY LTD/S issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.9-4.2 million, compared to the consensus revenue estimate of $5.35 million. What price target have analysts set for BWAY? 2 equities research analysts have issued 12-month target prices for BRAINSWAY LTD/S's shares. Their forecasts range from $9.00 to $13.00. On average, they expect BRAINSWAY LTD/S's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for BRAINSWAY LTD/S. Has BRAINSWAY LTD/S been receiving favorable news coverage? News articles about BWAY stock have been trending very positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BRAINSWAY LTD/S earned a news impact score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutBRAINSWAY LTD/S. Who are some of BRAINSWAY LTD/S's key competitors? Some companies that are related to BRAINSWAY LTD/S include Utah Medical Products (UTMD), SeaSpine (SPNE), Alphatec (ATEC), Iradimed (IRMD), iCAD (ICAD), Liquidia Technologies (LQDA), Pulse Biosciences (PLSE), Accuray (ARAY), Restoration Robotics (HAIR), Westaim (WEDXF), TELA Bio (TELA), Soliton (SOLY), Apyx Medical (APYX), BeyondAirInc . (XAIR) and RenovaCare (RCAR). View all competitors. What other stocks do shareholders of BRAINSWAY LTD/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BRAINSWAY LTD/S investors own include Gilead Sciences (GILD), Goodrich Petroleum (GDP), Goodrich Petroleum (GDP), Neuronetics (STIM), AbbVie (ABBV), Carnival (CCL), Energy Transfer LP Unit (ET), Flexion Therapeutics (FLXN), General Motors (GM) and Inovio Pharmaceuticals (INO). Who are BRAINSWAY LTD/S's key executives? BRAINSWAY LTD/S's management team includes the following people: Dr. David Zacut, Founder & Chairman (Age 66)Prof. Abraham Zangen, Founder & Member of the Scientific Advisory Board (Age 49)Dr. Yiftach Roth, Founder & Chief Scientist (Age 48)Mr. Hadar Levy, Chief Financial Officer (Age 45)Mr. Ronen Segal, Chief Technology Officer (Age 46) When did BRAINSWAY LTD/S IPO? (BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO. What is BRAINSWAY LTD/S's stock symbol? BRAINSWAY LTD/S trades on the NASDAQ under the ticker symbol "BWAY." Who are BRAINSWAY LTD/S's major shareholders? BRAINSWAY LTD/S's stock is owned by many different institutional and retail investors. Top institutional investors include Cowen AND Company LLC (3.18%), Phoenix Holdings Ltd. (2.98%), Raymond James & Associates (0.17%), Victory Capital Management Inc. (0.11%), Victory Capital Management Inc. (0.11%) and Meitav Dash Investments Ltd. (0.11%). Which institutional investors are selling BRAINSWAY LTD/S stock? BWAY stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Meitav Dash Investments Ltd., Victory Capital Management Inc., and Victory Capital Management Inc.. Which institutional investors are buying BRAINSWAY LTD/S stock? BWAY stock was acquired by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, and Phoenix Holdings Ltd.. How do I buy shares of BRAINSWAY LTD/S? Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BRAINSWAY LTD/S's stock price today? One share of BWAY stock can currently be purchased for approximately $8.27. How big of a company is BRAINSWAY LTD/S? BRAINSWAY LTD/S has a market capitalization of $89.48 million and generates $23.10 million in revenue each year. The company earns $-10,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. BRAINSWAY LTD/S employs 96 workers across the globe. What is BRAINSWAY LTD/S's official website? The official website for BRAINSWAY LTD/S is www.brainsway.com. How can I contact BRAINSWAY LTD/S? BRAINSWAY LTD/S's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at 972-2581-3140 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
